Abstract
Introduction: Type 2 diabetes is a risk factor for dementia and Parkinson's disease (PD). Drug treatments for diabetes, such as metformin, could be used as potential novel treatments for these neurological conditions. Using medical records from the USA (OPTUM) we aimed to assess the association of metformin with all cause dementia, dementia subtypes, and PD compared to sulfonylureas. Research Design and Methods: A new user comparator study design was conducted in patients >50 years old with diabetes who were new users of metformin or sulfonylureas between 2006-2018. Primary outcomes were all cause dementia and PD. Secondary outcomes were Alzheimer's disease (AD), vascular dementia (VD), and mild cognitive impairment (MCI). Cox proportional hazard models with inverse probability of treatment weighting (IPTW) were used to estimate the hazard ratios (HR). Sub analyses included stratification by age, race, renal function, and glycemic control. Results: We identified 96,140 and 16,451 new users of metformin and sulfonylureas, respectively. Mean age was 66.4 +/- 8.2 years (48% male, 83% Caucasian). Over the 5-year follow-up, 3,207 patients developed all cause dementia (2,256 [2.3%] metformin, 951 [5.8%] sulfonylurea users) and 760 patients developed PD (625 [0.7%] metformin, 135 [0.8%] sulfonylurea users). After IPTW, HRs for all cause dementia and PD were 0.80 (95%CI 0.73-0.88) and 1.00 (95%CI 0.79-1.27). HRs for AD, VD and MCI were 0.81 (0.70-0.94), 0.79 (0.63-0.99) and 0.91 (0.79-1.04). Stronger associations were observed in patients who were younger (<75 years old), Caucasian, and with moderate renal function. Conclusions: Metformin users compared with sulfonylureas users were associated with a lower risk of all cause dementia, AD and VD but not with PD or MCI. Age and renal function modified risk reduction. Our findings support the hypothesis that metformin provides more neuroprotection for dementia than sulfonylureas but not for PD, but further work is required to assess causality.
Competing Interest Statement
Alejo J. Nevado-Holgado has received funding from Janssen Pharmaceuticals, GlaxoSmithKline and Ono Pharma. QSL is an employee of Janssen Research & Development, LLC, of Johnson & Johnson, and may hold equity in Johnson & Johnson. All other authors declare no conflicts of interest
Funding Statement
This work was supported by Janssen Pharmaceuticals. Lenore J. Launer is supported by the National Institute on Aging Intramural Research Programme, US. Additional funds were provided by Rosetrees Trust (M937) and John Black Charitable Fund (ID A2926). The funding sources has no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Optum claims databases were reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval, as this research project did not involve human subjects research
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be obtained from a third party (OPTUM) and are not publicly available.
